Human Drug Regulation -- Approvals, Promotion, Marketing, Warnings, Accountability, and Postmarket Surveillance

Human Drug Regulation -- Approvals, Promotion, Marketing, Warnings, Accountability, and Postmarket Surveillance

by Roseann B. Termini, Esq.
     
 

This volume focuses on significant issues and legal cases in Human Drug Law. Volume V contains United States Supreme Court legal decisions that have impacted on the practice of pharmaceutical regulatory law. The United States Food and Drug Administration’s (FDA) mission, in accordance with the Federal Food, Drug and Cosmetic Act (FDCA), is to protect the public health… See more details below

Overview

This volume focuses on significant issues and legal cases in Human Drug Law. Volume V contains United States Supreme Court legal decisions that have impacted on the practice of pharmaceutical regulatory law. The United States Food and Drug Administration’s (FDA) mission, in accordance with the Federal Food, Drug and Cosmetic Act (FDCA), is to protect the public health and safety. This volume imparts a comprehensive analysis of drug law topics such as significant legislation, the Food and Drug Administration approval mechanisms for both new and generic drugs as well as biosimilars investigational drugs, direct to consumer advertising, “off label” enforcement, corporate accountability, drug reimportation, pharmacy compounding, counterfeit products and post market surveillance.
Information about the drug development process, from test-tube to new drug application review, the investigational drug review process and experimental treatments is provided. Details about generic drug products are covered and recent United States Supreme Court cases such as Mutual Pharmaceutical are included. The impact of copyright infringement is discussed in the decision of Smithkline Beecham Consumer Health Care, L.P. v. Watson Pharmaceuticals. Other important topics include bioequivalence, the MedWatch program and user fees and over-the-counter product labeling. This volume contains information on advertising, includes a dis-cussion of off label promotion, and legal decisions. For example, in Washington Legal Foundation v. Henney, the court invalidated the restrictions imposed by FDA on off-label uses because of First Amendment violations. The decisions of Perez, Schering Plough and Johnson distinguish the impact of direct-to-consumer promotion on the learned intermediary doctrine. The decision of Thompson v. Western States Medical Center invalidated Section 127 of FDAMA concerning promotion of pharmacy compounding. This volume contains cases about duty to warn issues including that of the manufacturer, physician and pharmacist.
Landmark cases involving the legal concept of preemption are included as well. Preemption is a legal term of art that emanates from the Supremacy Clause (Article VI, clause 2) of the United States Constitution. Article VI, clause 2 prohibits states from enacting laws that conflict with federal law unless the federal law contains explicit preemption language. The 2009 landmark United States Supreme Court decision, Wyeth v. Levine, concerned a brand name drug and the ability to bring a lawsuit in state court. Conversely, another United States Supreme Court case decided in 2011, Pliva v. Mensing involved a generic drug and held preemption prevailed. The United States Supreme Court in the 2011 Sorrell decision determined that a State regulation precluding the sale of data violated the First Amendment. Finally, the landmark Actavis Supreme Court decision concerning pay-for-delay is included. Each chapter contains critical analysis issues to explore.

Read More

Product Details

ISBN-13:
2940016720418
Publisher:
Forti Publications
Publication date:
02/23/2015
Series:
Food and Drug Law , #5
Sold by:
Barnes & Noble
Format:
NOOK Book
File size:
1 MB

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >